Citigroup: Japanese bond yields may have reached their peak, clearer fiscal outlook will enhance investment appeal
Citigroup strategists believe that Japanese government bond yields may be approaching their peak, and they expect financial institutions to increase investments in Japanese bonds as the country's fiscal policy outlook becomes clearer.
According to Jinse Finance, Citigroup strategist Tomohisa Fujiki believes that Japanese government bond yields may have reached their peak, and expects financial institutions to increase investments in Japanese bonds as Japan's fiscal policy outlook becomes clearer.
In a report on October 5, Tomohisa Fujiki wrote, "Japanese government bonds are becoming increasingly attractive." He stated that Japan's potential growth rate has not changed significantly, and if inflation stabilizes around 2%, the reasonable level for the benchmark 10-year government bond yield should be between 2.5% and 3.0%. Citigroup expects that as the market further prices in the Bank of Japan's future rate hike expectations and the supply-demand dynamics of Japanese bonds improve, the yield curve of Japanese government bonds will flatten.
Driven by concerns over inflation fueled by energy prices, the Bank of Japan withdrawing from the bond market, market expectations of faster monetary policy tightening by the Bank of Japan, worries about the Japanese government's fiscal discipline, and the global bond selloff, Japanese government bond yields have continued to climb. Last month, Japan's 10-year government bond yield rose above 3% for the first time and was at 3.116% at the time of writing; the 30-year government bond yield continued to hit new highs, reaching up to 4.279% during the day.
However, as the global bond market shifts its focus to France's fiscal issues, some investors appear to have begun turning to Japanese government bonds and are considering selling French bonds. Attracted by high yields, both the 2-year and 40-year Japanese government bond auctions at the end of September demonstrated strong investor demand.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering
On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)
BUZZ-AMD shares rise on plans to increase chip supply
October 6 — U.S. chipmaker Advanced Micro Devices (AMD.O) saw its shares rise 1.5% in pre-market trading, reaching $641.10. CEO Lisa Su stated that as AMD races to meet surging demand in the artificial intelligence sector, the company plans to significantly boost chip supply by 2027 (link). Su also noted that AMD is working closely with memory chip manufacturers to ensure sufficient supply; her remarks come ahead of her scheduled visit to South Korea later on Tuesday. At least two brokerage firms, including Citigroup, have raised their price targets for the stock, according to data compiled by LSEG. Out of 56 brokerages, 47 rate AMD as a “buy” or higher, and 9 rate it as “hold”; the median price target is $616, per LSEG data. As of yesterday’s close, the stock has gained over 100% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translations.)
New York securities industry targets profits of 90 billions USD! Goldman Sachs (GS.US) breaks quarterly records three times, Wall Street bonuses to hit all-time high
Profits of the New York securities industry are expected to surpass 90 billions USD, exceeding last year’s record of 65.1 billions USD, with bonuses potentially reaching all-time highs; underwriting income has increased by 68%, contributing 26.3 billions USD to state finances.
Citigroup (C.US) accelerates promotion pace to counter private equity headhunting
Citi (C.US) is shortening the time required for investment banking analysts to be promoted to associates in order to attract and retain top talent in a highly competitive job market.
Crypto prices
More
